- Home
- ACTU vs FATE Comparison
ACTU vs FATE Comparison
Compare ACTU & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACTU
- FATE
- Stock Information
- Founded
- ACTU 2015
- FATE 2007
- Country
- ACTU United States
- FATE United States
- Employees
- ACTU N/A
- FATE N/A
- Industry
- ACTU
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACTU
- FATE Health Care
- Exchange
- ACTU NYSE
- FATE Nasdaq
- Market Cap
- ACTU 135.0M
- FATE 152.4M
- IPO Year
- ACTU 2024
- FATE 2013
- Fundamental
- Price
- ACTU $10.35
- FATE $1.04
- Analyst Decision
- ACTU Strong Buy
- FATE Hold
- Analyst Count
- ACTU 1
- FATE 8
- Target Price
- ACTU $20.00
- FATE $5.43
- AVG Volume (30 Days)
- ACTU 71.1K
- FATE 2.1M
- Earning Date
- ACTU 05-21-2025
- FATE 05-20-2025
- Dividend Yield
- ACTU N/A
- FATE N/A
- EPS Growth
- ACTU N/A
- FATE N/A
- EPS
- ACTU N/A
- FATE N/A
- Revenue
- ACTU N/A
- FATE $13,631,000.00
- Revenue This Year
- ACTU N/A
- FATE N/A
- Revenue Next Year
- ACTU N/A
- FATE N/A
- P/E Ratio
- ACTU N/A
- FATE N/A
- Revenue Growth
- ACTU N/A
- FATE N/A
- 52 Week Low
- ACTU $5.51
- FATE $0.66
- 52 Week High
- ACTU $11.73
- FATE $5.92
- Technical
- Relative Strength Index (RSI)
- ACTU N/A
- FATE 46.67
- Support Level
- ACTU N/A
- FATE $0.91
- Resistance Level
- ACTU N/A
- FATE $1.34
- Average True Range (ATR)
- ACTU 0.00
- FATE 0.13
- MACD
- ACTU 0.00
- FATE -0.03
- Stochastic Oscillator
- ACTU 0.00
- FATE 22.41
About ACTU ACTUATE THERAPEUTICS INC
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.